Meta content: Fluence Corporation Limited is an ASX-listed company (ticker: FLC). This article provides detailed insights into the company's operations, market position, and Investment thesis.

Fluence Corporation Limited (ASX:FLC) is a global water and wastewater treatment company that has spent recent years working to turn strong Revenue growth into sustainable profitability. The most important verified point for investors is that the turnaround is showing up in the numbers. For the 2025 financial year Fluence reported revenue of US$78.4 million, up more than 52 per cent, and positive EBITDA of US$4.0 million, a swing from a US$4.0 million loss the year before. A recently won US$3.7 million industrial water contract in Texas illustrates the higher-value work the company is now chasing.

What Just Happened?

The clearest recent development is a strategic industrial water treatment contract in Texas valued at about US$3.7 million. Under the award, Fluence will design and build an ultrafiltration and reverse osmosis plant capable of treating up to 1.5 million gallons per day of groundwater drawn from an on-site well. The treated water will Supply cooling tower make-up for a major United States manufacturer, reducing its reliance on municipal supply.

Fluence highlighted that the system is designed for greater than 90 per cent water recovery, a selling point in water-stressed regions, with commissioning expected by the end of 2026. The contract fits the company's stated strategy of expanding its Smart Product Solutions and recurring-revenue offerings for industrial customers.

The award came against a backdrop of improving financials. Alongside the FY2025 result, Fluence reported first-quarter 2026 revenue of US$17.2 million and an order Backlog of about US$64.4 million at 31 March 2026, and it guided to double-digit revenue growth for the 2026 financial year.

Why It Matters

For a company that has long grown its Top Line without consistently making money, the shift to positive EBITDA is the headline change. It suggests the Business has reached a scale where revenue growth can drop through to Earnings rather than being consumed by costs. That matters because it reduces the reliance on external funding and gives management more room to invest.

The Texas contract matters for a different reason. Industrial water treatment for large manufacturers tends to be higher Margin and stickier than one-off municipal projects, and it can lead to ongoing service and maintenance revenue. Winning this kind of work supports Fluence's push toward Smart Product Solutions and recurring income, which is exactly the mix investors have wanted to see. A healthy backlog also gives some forward visibility on revenue.

The Bigger Picture

Fluence Corporation designs, builds and operates water, wastewater and water reuse solutions for municipal and industrial customers around the world. Its technology portfolio includes membrane aerated biofilm reactor systems and packaged, modular treatment plants that can be deployed relatively quickly, along with ultrafiltration and reverse osmosis systems of the type used in the Texas project.

The company operates across multiple regions, with activity spanning the Americas, Asia and other markets, and it has pursued a strategy of standardised, repeatable products alongside larger engineered projects. Management has emphasised Smart Product Solutions, a range of pre-engineered systems, and Recurring Revenue from operations and services, as the path to steadier, higher-quality earnings.

In simple terms, Fluence sells the equipment and know-how that treats dirty or brackish water so it can be reused or safely discharged. Demand is underpinned by long-term themes: water scarcity, tightening environmental rules and the need for industry to secure reliable supply. The investment question has always been whether Fluence can convert that demand into consistent profit, and the recent results suggest progress on that front.

What Could Drive the Shares Next?

The most immediate drivers are execution and the order book. Delivery of the FY2026 double-digit revenue growth the company has guided to, and evidence that EBITDA remains positive or improves, would reinforce the turnaround narrative. Growth in the backlog beyond the US$64.4 million reported at the end of March would point to continued demand.

New industrial and recurring-revenue contracts in the mould of the Texas award are the type of announcements that could support sentiment, as would progress on the seawater desalination work the company has flagged in markets such as Vietnam. Resolving its funding arrangements, including the Credit Facility discussions management has referenced, would also remove an overhang. Broader interest in water infrastructure as an investment theme provides a supportive backdrop.

Risks Investors Should Watch

Despite the improved result, Fluence remains a small company operating in a capital-intensive, project-driven industry. Revenue can be lumpy, tied to the timing of large contracts, and margins can be squeezed by cost Inflation or project delays. A single problem project can materially affect a period's earnings.

Funding and working Capital are worth watching. Building treatment plants requires cash ahead of payment, and the company has been in discussions around its credit facilities; any tightening of finance could constrain growth or force a capital raising that dilutes shareholders. Fluence also operates internationally, which exposes it to currency movements and country-specific risks. Competition in water treatment is intense, from both large engineering groups and nimble specialists. Finally, as a small-cap, the shares can be volatile and less liquid than those of larger peers.

Bottom Line

Fluence Corporation has reached an important inflection point, pairing rapid revenue growth with a swing to positive EBITDA and a backlog that gives some forward visibility. The Texas industrial water contract is a small deal in dollar terms, but it fits the strategy that matters most: higher-value, recurring industrial work rather than one-off projects. For ASX investors, the story is now less about whether Fluence can grow and more about whether it can hold onto profitability, fund its growth without heavy dilution and keep winning the right kind of contracts. The FY2026 delivery against guidance, and the direction of the order book, will show whether the recent progress marks a durable turn or simply a good year.